The QualityStocks Daily Thursday, February 13th, 2020

Today's Top 3 Investment Newsletters

CannabisNewsWire (GGBXF) +66.11%

StocksToBuyNow (GNPX) +51.38%

QualityStocks (XALL) +36.00%

The QualityStocks Daily Stock List

Acreage Holdings, Inc. (ACRGF)

Street Insider, New Cannabis Ventures, Investors Observer, The Cannabis Investor, Microcap Daily, TipRanks, Street Insider, TMXmoney, Dividend Investor, Investing News, InvestorsHub, Proactive Investors, Investing.com, MarketBeat, Market Screener, OTC Markets, TradingView, Stockwatch, and Equities reported beforehand on Acreage Holdings, Inc. (ACRGF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Acreage Holdings, Inc. is one of the largest vertically integrated, multi-state operators of cannabis licenses and assets in the U.S. The Company owns licenses to operate or has management or consulting services or other agreements in place with license holders to assist in operations in 20 States (including pending acquisitions). Acreage Holdings is based in New York, New York. The Company lists on the OTC Markets’ OTCQX.

From seed to sale, Acreage Holdings’ emphasis is creating industry standards that deliver the highest quality products and experiences. The Company’s business model includes Cultivation, Process Manufacturing, Dispensing, and Consumer Brands.

Acreage’s national retail store brand, The Botanist, debuted in 2018. The Botanist provides an immersive, educational hub for people who desire to live a balanced and socially responsible lifestyle. Acreage’s products are inventively formulated to help consumers experience a more holistic path to health and wellness.

Along with the Botanist, Acreage has its Prime brand. This is a premier brand of medical cannabis, from seed to sale. Prime focuses on advancing health and wellness and delivering top-quality, pesticide-free products designed for precise dosing and medicating. In addition, Acreage has its Live Resin Project brand. Live Resin Project offers a unique line of vapes and concentrates crafted using innovative extraction methods that use the whole cannabis plant. The Company also has its Natural Wonder brand. This is a lifestyle brand of fast-acting, discreet, and effective breath sprays formulated with natural ingredients and combined with premier cannabinoids.

On November 15, 2019, certain of Acreage Holdings’ subsidiaries and Compassionate Care Foundation, Inc. (CCF), a New Jersey vertically integrated cannabis non-profit corporation, entered into a Reorganization Agreement. Thus, Acreage Holdings will acquire 100 percent of the equity interests in CCF, and then consolidate their financials. The closing of the transaction is subject to State approval. CCF’s vertically integrated operations include licenses for cultivation, manufacturing & processing, and three retail dispensaries.

In January, Acreage Holdings announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), has expired with regarding the proposed acquisition of Deep Roots Medical LLC (d/b/a Deep Roots Harvest). The expiration of the waiting period under the HSR Act satisfies one condition required to close the transaction, which remains subject to certain other customary closing conditions. Deep Roots Harvest is a vertically integrated cannabis operator in the State of Nevada.

On April 18, 2019, Acreage Holdings announced that its subsidiary, High Street Capital Partners, LLC (HSCP), entered into an agreement to acquire 100 percent of Deep Roots Harvest for a total transaction value of $120 million to be paid in equity of HSCP and cash.

Acreage Holdings, Inc. (ACRGF), closed Thursday's trading session at $5.05, up 1.00%, on 162,068 volume with 527 trades. The average volume for the last 3 months is 324,040 and the stock's 52-week low/high is $3.83999991/$30.00.

chart

Blueberries Medical Corp. (BBRRF)

Small Cap Power, NIC Investors, Profit Confidential, Midas Letter, InvestorX, Wallmine, Morningstar, Technical420, Dividend Investor, Stockhouse, Financial Buzz, InvestorsHub, Street Insider, PR Newswire, Market Screener, Dividend.com, Stockwatch, GlobeNewswire, Wallet Investor, Nasdaq, Investing.com, TradingView, and BioPortfolio reported previously on Blueberries Medical Corp. (BBRRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Blueberries Medical Corp. is a Latin American licensed producer of medicinal cannabis and cannabis-derived products. It is a producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia and operations now being established in Argentina. In Argentina, Blueberries Medical is advancing a pilot project in a joint venture (JV) with the state-owned company Cannava. Blueberries Medical is based in Bogotá, Colombia. The Company lists on the OTC Markets’ OTCQB.

A specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology, and marketing leads Blueberries Medical. The Company is fully licensed for the cultivation, production, domestic distribution, and international export of CBD (cannabidiol) and THC-based (tetrahydrocannabinol) medical cannabis in Colombia.

Blueberries Medical’s combination of foremost scientific expertise, agricultural advantages, and distribution arrangements has positioned it to become a top global supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products. The Company has a large cultivation footprint with scalable growing capacity through contract growers. It has 142 exclusive Colombian cannabis strains with high CBD and THC contents. Additionally, it has strong global partnerships for product development and distribution.

Regarding cannabis oil extracts, Blueberries Medical develops high-end medicinal products for the treatment of numerous human conditions. The Company works together with small producers in the region of the Bogota Savanna and supplies medicinal cannabis products to the national and worldwide market.

Blueberries Medical has commissioned the first extraction line at its 2,800 m2 (30,138 ft2) state-of-the-art extraction facility, strategically located in Cundinamarca, the region with the highest concentration of licensed cannabis producers. The initial extraction line is completely operational and is in a modern and secure industrial park 30 minutes outside of Bogota.

The initial capacity of this facility is 80,000kg/year of dried flower with the ability to accommodate considerable expansion of up to five additional extraction lines. The facility uses supercritical CO2 extraction technology to produce the highest quality cannabis oil. The newly commissioned equipment will provide sufficient capacity for Blueberries Medical to process biomass from the Company’s vertically integrated cultivation operations and also its contract growers and other licensed producers.

Blueberries Medical Corp. (BBRRF), closed Thursday's trading session at $0.09098, off by 4.2316%, on 52,633 volume with 18 trades. The average volume for the last 3 months is 73,698 and the stock's 52-week low/high is $0.061/$0.649999976.

chart

Charlotte's Web Holdings, Inc. (CWBHF)

Alpha Stock News, Profit Confidential, Insider Financial, OTC Markets, Market Realist, New Cannabis Ventures, Pot Stock News, NIC Investors, MJGlobal Report, Equities, InvestorsHub, GuruFocus, TipRanks, TradingView, Investor Place, Dividend Investor, YCharts, Barchart, Marijuana Stocks, Simply Wall St, Stockwatch, and Seeking Alpha reported earlier on Charlotte's Web Holdings, Inc. (CWBHF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, Charlotte's Web Holdings, Inc. is the market leader in hemp CBD (cannabidiol) extract products. The Company’s product categories include CBD oil tinctures (liquid products), CBD capsules, CBD topicals, and CBD pet products. Charlotte's Web hemp-derived CBD extracts sell via select distributors, brick and mortar retailers, and online through the Company's website. The Company previously went by the name Stanley Brothers Holdings, Inc. It changed its name to Charlotte's Web Holdings, Inc. in July of 2018. Founded in 2013, the Company is based in Boulder, Colorado.

The rate Charlotte's Web Holdings pays for agricultural products reflects a fair and sustainable rate. This drives higher quality yield, encourages good farming practices, and supports U.S. farming communities. The Company's premium quality products begin with proprietary hemp genetics responsibly manufactured into hemp-derived CBD extracts naturally containing a full spectrum of phytocannabinoids. These include CBD, terpenes, flavonoids, as well as other beneficial hemp compounds.

Charlotte’s Web products meet or surpass industry standards for purity. These products are tested in-house and by major independent third-party laboratories. Therefore, the Company can create the highest quality products in the industry, derived only from family farms in the United States - no imported hemp or hemp extracts.

At the end of January, Charlotte's Web Holdings announced management appointments reflecting the Company's distinguished cultivation excellence, and also its increased activities in public and regulatory affairs, sciences, data, and sustainability. Mr. Jared Stanley, Company Co-Founder and Vice President of Cultivation Operations, was promoted to the newly created role of Chief Cultivation Officer, reporting directly to the Chief Executive Officer, Deanie Elsner.

Mr. Stanley has established cultivation excellence for Charlotte’s Web over the past six years with industry leading expertise. The appointment reflects Mr. Stanley's successful supervision in the execution of every step of the cultivation process. Cultivation is a critical component of the Company’s supply chain as it ensures consistency of high-quality products.

Kelly Shea has joined Charlotte's Web Holdings in the newly created role of Senior Vice President of Government Affairs & Corporate Communications, overseeing Federal and State Government Relations, Corporate Social Responsibility, Communications, and Customer Education. Paul Lanham, Chief Data, IT and ECommerce Officer, will now report to Deanie Elsner. Mr. Lanham supervises the business analytics, digital strategy, and direct-to-the-consumer ecommerce business to bring visibility to operations, enabling better reach and customer service.

Charlotte's Web Holdings, Inc. (CWBHF), closed Thursday's trading session at $6.338, off by 1.1232%, on 421,242 volume with 1,456 trades. The average volume for the last 3 months is 587,795 and the stock's 52-week low/high is $6.21000003/$25.25.

chart

Emerald Organic Products, Inc. (EMOR)

Zacks, OTC Markets, Central Charts, Value Forum, YCharts, wallstreet-online, Cannabis Life News, Financial Buzz, Biospace, The Life Sciences Report, Cash Crop Today, TradingView, Barchart, Stockopedia, and GlobeNewswire reported earlier on Emerald Organic Products, Inc. (EMOR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Emerald Organic Products, Inc. is a diversified CBD (cannabidiol) products enterprise. The Company, by way of its flagship Pura Vida brand, has developed and recently commercialized a line of vitamins and supplements with certain proprietary CBD health and wellness products that will be marketed nationally and in certain foreign countries. Emerald Organic Products has its corporate headquarters in the State of New York. The Company lists on the OTC Markets.

Emerald Organic Products markets its products by way of diverse marketing and sales distribution channels including experienced wholesale distributors and a professional e-commerce platform www.puravidavitamins.com. The hemp-based proprietary Pura Vida Vitamins products include CBD vitamins, chewable CBD gummies, and gummy bears, vaporization CBD liquids, drinks, CBD tinctures, CBD cosmetics, and others. The Company has entered into a binding term sheet to license the therapeutic candidates Eltoprazine, ESS and MANF from Amarantus Bioscience Holdings, Inc. (AMBS).

This past November, Emerald Organic Products announced that it signed an agreement to acquire a controlling 51 percent stake in Bezalel’s Jewelry, Inc., which will offer Emerald accretive opportunities for CBD vending and more. Bezalel’s Jewelry is a vending machine manufacturing and distributing company.

Mr. Ian Parker, Chief Executive Officer and Executive Chairman of Emerald Organic Products, said in November 2019, “Emerald Organic Products’ all stock transaction with Bezalel’s will allow Emerald to immediately begin deploying and offering a Patent protected unique vending machine in select markets. These unique vending machines employ facial recognition software and can positively identify people with I.D. from 143 countries worldwide. This allows for the vending of age restricted, and identity restricted products. We are particularly excited about the machines presentation, which allows for HD quality advertising offering a significant revenue opportunity.”

Last month, Amarantus Bioscience Holdings, Inc. announced that it completed an exclusive global sublicense agreement for development rights of Cutanogen Corporation’s and MANF Therapeutics, Inc.’s pipelines to Emerald Organic Products. Emerald now has development rights to Engineered Skin Substitute (ESS), mesencephalic astrocyte-derived neurotrophic factor (MANF), and PhenoGuard for all applications. Amarantus Bioscience is a biotechnology holding company pursuing proprietary therapeutics and diagnostics via its subsidiaries.

With this executed agreement, Amarantus Bioscience is receiving an up-front payment of preferred stock in Emerald Organic Products to be valued at a minimum of $66.6 million (the Preferred). It will receive single digit royalties, with a right to buy into up to double-digit royalties until April 2022. The Preferred is convertible into 33,333,333 shares of Emerald common stock in April of 2022.

Emerald Organic Products, Inc. (EMOR), closed Thursday's trading session at $2.25, even for the day, on 5 volume. The average volume for the last 3 months is 593 and the stock's 52-week low/high is $0.50999999/$6.50.

chart

Mastermind, Inc. (MMND)

Zacks, Equities, last10k, TMXmoney, Market Screener, InvestorsHub, TipRanks, Street Insider, Stockhouse, TeleTrader, Financial Buzz, Stockwatch, YCharts, Stockopedia, OTC Markets, Market Wire News, Corporate Information, and Simply Wall St reported beforehand on Mastermind, Inc. (MMND), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Mastermind, Inc. is a top involvement marketing agency listed on the OTC Markets’ OTCQB. The Company designs, creates, and activates marketing campaigns for global brands. Mastermind has a complete, data-driven approach. This approach drives brand consideration, trial, loyalty, and advocacy. The Company is a subsidiary of Mastermind Marketing, Inc. A foremost vertically-integrated digital marketing company, Mastermind has its head office in Atlanta, Georgia.

Mastermind has more than three decades of experience in dozens of industries helping involve people with brands in ways that inspire them to take action. The Company’s expertise areas include Content, Digital, Influencer, Social, Promotion, Channel Optimization, as well as Digital Issues Management. This allows Mastermind to create and execute multi-dimensional campaigns that drive results.

The Company has a data-driven process. This involves strategy and planning - objective setting, goal establishment, data and market analysis. Mastermind creates and manages digital content, social media and sharing campaigns, mobile merchandising, and communications and branding programs. Furthermore, the Company designs websites. Mastermind designs, creates, and develops branding and marketing campaigns chiefly for large corporate clients.

Mastermind is creating predictive analytic dashboards to optimize marketing decisions and drive more conversions for Fortune 500 brands. It aggregates and integrates disparate client data sources into custom algorithms to produce unique dashboards, which provide a tailored, on-demand, 360° view of the client’s business.

Last month, Mastermind announced financial results for the Fiscal Year (FY) ended September 30, 2019. Selected results for FY 2019 include Total Revenue of $4.0 million versus Revenue of $5.2 million for Fiscal 2018; Gross Profit of $1.8 million versus $3.2 million for Fiscal 2018; and a Net Loss of $0.8 million versus Net Income of $0.9 million for Fiscal 2018.

Mr. Dan Dodson, Mastermind Chief Executive Officer, said, “Fiscal 2019 brought significant revenue and expense challenges that we were able to successfully navigate. We are confident that 2020 will be a strong year. In FYE 2019, approximately $1.7 million in expected revenue did not materialize due to (1) the merger of a major client, and (2) a surprise bankruptcy filing of another client.”

Mastermind, Inc. (MMND), closed Thursday's trading session at $0.655, even for the day, on 27 volume with 1 trade. The average volume for the last 3 months is 325 and the stock's 52-week low/high is $0.540000021/$2.40000009.

chart

Pure Gold Mining, Inc. (LRTNF)

Street Insider, Resource World, StockInvest.us, Mining Stock Valuator, Dividend Investor, Capital Cube, TradingView, YCharts, GuruFocus, Morningstar, InvestorsHub, Market Screener, MarketWatch, Proactive Investors, 4-Traders, Nasdaq, Stockhouse, Wallet Investor, Wallmine, Northern Miner, Barchart, Ceo.ca, Cambridge House International, Dividend.com, and Seeking Alpha reported earlier on Pure Gold Mining, Inc. (LRTNF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Pure Gold Mining, Inc. is an exploration stage company based in Vancouver, British Columbia. It engages in the acquisition, exploration, and development of gold, and other precious and base metal properties in Canada. The Company is building Canada’s highest-grade gold development project, the Pure Gold Red Lake Mine. Project financing is secured and the Pure Gold Red Lake Mine is on course to deliver first production into a rising gold market in late 2020. Pure Gold Mining lists on the OTC Markets.

The orebody at the Pure Gold Red Lake Mine is open for expansion. It forms a part of a seven kilometer long mineral system under active exploration. The Company states that there is opportunity for transformative growth via discovery.

With the start of production, Pure Gold Mining will be joining the small, elite group of well-funded gold producers with high-grade, multi-million ounce deposits located in prolific, mining-friendly jurisdictions such as Red Lake, Ontario. The Company states that the Pure Gold Mine ore body is an exceptional foundation on which to build a gold mining company.

The Pure Gold Red Lake Mine has Probable Mineral Reserves of 3.5 Mt at 9.0 g/t containing 1.0 million ounces of gold included in a Mineral Resource of 7,196,000 Indicated tonnes grading 8.9 g/t gold for 2,063,000 ounces of gold and 1,880,000 Inferred tonnes grading 7.7 g/t gold for 467,000 ounces of gold. The Pure Gold Red Lake Mine is the highest grade development stage gold deposit in Canada and will be in the top 8 percentile worldwide when in production.

This past December, Pure Gold Mining announced that exploration drilling near the Madsen Red Lake Mine, presently under construction, intersected high-grade gold mineralization from a second drill hole targeting the widespread gap between the Company’s 8 zone at depth and the Russet South zone, which outcrops at surface. This latest drill hole confirms the discovery potential of this new target area. In addition, it supports continuity of the gold system between Russet South and 8 zone.

Recently, Pure Gold Mining announced that mine development at the Pure Gold Red Lake Mine, initiated as part of the test mining program, resumed, and exploration drilling in close proximity to this development intersected high-grade gold mineralization from infill and step-out drill holes. Drilling tested potential for growth of ore zones, which will provide initial feed for the mine processing plant. Drilling has yielded positive results suggesting strong mine continuity and the potential for mining stope expansion.

Drilling results highlights include 24.9 g/t gold over 1.0 meter from drill hole PG19-708; and 34.1 g/t gold over 2.2 meters from drill hole PG19-710; including 64.6 g/t gold over 1.0 meter. Drilling results highlights also include 33.1 g/t gold over 3.4 meters from drill hole PG19-719; including 79.4 g/t gold over 1.4 meters; and 13.2 g/t gold over 6.3 meters from drill hole PG19-735; including 26.3 g/t gold over 2.0 meters.

Pure Gold Mining, Inc. (LRTNF), closed Thursday's trading session at $0.583, off by 1.0775%, on 168,226 volume with 83 trades. The average volume for the last 3 months is 276,701 and the stock's 52-week low/high is $0.354999989/$0.683099985.

chart

Sigma Lithium Resources Corporation (SGMLF)

OTC Markets, Proactive Investors, MineStat, The Prospector News, Junior Mining Network, Penny Stock Hub, OTC.Watch, Northern Miner, TipRanks, Morningstar, MarketWatch, GlobeNewswire, Wallet Investor, TMXmoney, Market Screener, Seeking Alpha, Canadian Insider, Nasdaq, Seeking Alpha, Barchart, Mining.com, Market Screener, Stockwatch, TradingView, and Canadian Mining Journal reported earlier on Sigma Lithium Resources Corporation (SGMLF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Sigma Lithium Resources Corporation is on course to becoming a premier supplier to the lithium battery industry around the world. The Company is developing a world-class, hard rock lithium deposit at its Grota do Cirilo property in Brazil, with ultra-high grade and exceptional mineralogy. Sigma shareholders include some of the top ESG (Environmental, Sustainability, Governance) focused institutional investors worldwide. OTCQB-listed, Sigma Lithium Resources is based in São Paulo, Brazil.

The Company plans to play a leading role in the worldwide lithium battery supply chain and thriving electric vehicle (EV) industry. Sigma Lithium Resources manages a green and sustainable mining operation. It commissioned its Phase I pilot plant and has produced greater than 100 tonnes of samples of battery grade spodumene lithium concentrate from its high-quality deposits.

Sigma Lithium Resources is strategically located in Brazil providing high quality battery grade spodumene concentrate. Sigma is a potential low cost, high margin producer. It has first-rate infrastructure and project access. The expectation is that this will result in manageable capital costs to production.

The Company has 28 mineral rights in four properties spread over 188 km2 and 18,887 hectares - with more than 200 lithium bearing pegmatites and 11 former historical lithium mines. The Grota do Cirilo property is its principal focus. Grota do Cirilo includes 10 mining concessions (mining production authorizations).

The projection is that Sigma Lithium Resources will produce 220,000 tonnes per year of high-quality battery-grade 6 percent lithium oxide concentrate, or spodumene, with one of the lowest levels of impurities in the world, which according to the studies completed so far will likely be one of the lowest-cost lithium mine operations globally. The Company is on track to attain commercial production by 2021 of its “green” 6% battery-grade lithium-concentrate with low impurities that will be engineered to customer specifications in the fast-growing lithium-ion battery supply chain.

A10 Investimentos and its affiliates (A10 Group) continues to support Sigma Lithium Resources in meeting its development and construction timetable and also strategic environmental and social ESG goals. On November 29, A10 Group provided the Company with a CAD6.6 million (USD5 million) senior unsecured revolving credit facility to complete the pre-feasibility study for the Barreiro deposit, to meet the current social-economic obligations under the environmental licensing, and for general corporate purposes. Sigma Lithium Resources continues its pre-feasibility study for the Barreiro deposit. Subject to completion of all related feasibility studies and assessments, the Company aims to boost Project production capacity of high-quality battery-grade 6% lithium concentrate to 440,000 tonnes per year from an initial 220,000 tonnes.

Sigma Lithium Resources Corporation (SGMLF), closed Thursday's trading session at $1.24, even for the day, on 350 volume. The average volume for the last 3 months is 305 and the stock's 52-week low/high is $1.19000005/$1.66999995.

chart

FingerMotion, Inc. (FNGR)

Stock Target Advisor, OTC Markets, Capital Cube, Stockwatch, Investors Hangout, Stockhouse, Real Investment Advice, Trading View, InvestorsHub, Street Insider, Simply Wall St, and Wallet Investor reported beforehand on FingerMotion, Inc. (FNGR), and today we report on the Company, here at the QualityStocks Daily Newsletter.

FingerMotion, Inc. is a U.S. FinTech (Financial Technology) company with mobile payment and recharge platform operations in the People’s Republic of China (PRC). It is one of five companies in China with access to wholesale rechargeable minutes by way of top-up credits on the mobile phone. The Company’s vision is to quickly grow its user base via organic means and have this growth develop into an ecosystem of users with high engagement rates using its unique applications.

JiuGe Information Technology is FingerMotion’s wholly-owned Chinese subsidiary. FingerMotion has its head office in China. The Company’s shares trade on the OTC Markets Group’s OTCQB.

FingerMotion is investing in research and development (R&D). Its chief area of emphasis is the development of “must have” applications for consumers and businesses. Its longer term focus is to develop a marketing platform capable of leveraging all the meta data collected by the leading telcos into a predictive model, which is able to isolate and extract consumer behavior and habits for future monetization.

FingerMotion is developing value added technologies to market to its users. The Company ultimately hopes to serve more than 1 billion users in the China market and eventually expand the model to other regional markets.

In late October 2019, FingerMotion announced its financial results for the quarter ended August 31, 2019. Chief Executive Officer, Mr. Martin Shen, said, “I am very pleased with the improvement in our JiuGe subsidiary, as we posted our first ever gross profit for the quarter. We believe this achievement has elevated us to an elite class of Chinese e-commerce businesses that have reached profitability.”

The latest financial results reflect an improved balance sheet and quarter-over-quarter growth. FingerMotion maintained momentum in their Revenues mainly driven by their strategic partnerships regarding top-up growth. Its Gross Transaction Volume (GTV) for Q2 was $181 million. This represents a 15 percent quarter over quarter increase in comparison to the $157 million realized in Q1. This translates to an annual run rate of $722 million.

The Company stated that the SMS business is also gaining noticeable traction. Moreover, the JiuGe subsidiary was awarded contracts to market China Mobile’s products and services online, in ShanXi and SiChuan provinces, which have a combined population of greater than 115 million people.

FingerMotion, Inc. (FNGR), closed Thursday's trading session at $1.25, up 31.5789%, on 9,970 volume with 19 trades. The average volume for the last 3 months is 3,453 and the stock's 52-week low/high is $0.510500013/$9.4499998.

chart

Parallax Health Sciences, Inc. (PRLX)

OTC Markets, Wallmine, Proactive Investors, last10k, Simply Wall St, Stockhouse, Wallet Investor, OTC Dynamics, Stockwatch, 4-Traders, PR Newswire, Market Exclusive, TradingView, GlobeNewswire, and InvestorsHub reported earlier on Parallax Health Sciences, Inc. (PRLX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, Parallax Health Sciences, Inc. is an outcome-driven connected healthcare company. It allows for cost-effective remote diagnosis, treatment and monitoring of patients via proprietary platforms of integrated products and services. The Company’s products and offerings capitalize on the digital transformation in healthcare for improved patient compliance, diagnosis and treatment, and support healthcare system cost savings and efficiencies. Parallax Health Sciences is headquartered in Santa Monica, California.

The Company concentrates on personalized patient healthcare through its wholly-owned subsidiaries, Parallax Health Management, Parallax Behavioral Health, and Parallax Diagnostics. Its interoperable novel applications provide patients point-of-care testing and monitoring with information communicated by way of internet-based mobile phone applications, which are agnostic as to operating system. They are built on highly sophisticated data analytics.

Information is retrieved real-time by physicians who are monitoring patients with chronic diseases or via biometric feedback for health-related behavior modification. Information is automated for integration into electronic health records.

Regarding Parallax Diagnostics, Parallax's Target Antigen Detection System (TADS) Diagnostic Platform is a Controlled Flow-Through Rapid Immunoassay Technology. It offers a variety of improved modifications and features to the traditional Flow-Through Immunoassay Test. With its Platform uniformity, vacuum pump, absorption layer for sample overflow, and complete compatibility with the Company’s optic reader, the Target System Diagnostics Platform is an inventive collection of tests for qualitative and quantitative detection of patient conditions.

Parallax Behavioral Health (PBH) provides consulting and software solutions to businesses and individuals. This is to improve value, margin, and performance through enhanced outcomes and lower cost mastery. PBH has its patented Intrinsic Code. It includes predictive-progressive analytics and goal optimization software. PBH is strategically positioned to enable users from large healthcare corporations to individuals take control of their outcomes.

Parallax Health Management provides remote monitoring solutions. These solutions are to support disease management and provide better care options for chronic conditions.

Recently, Parallax Health Sciences announced that it has retained Alston & Bird, a foremost national law firm. Alston & Bird, with more than 800 attorneys, has offices in Atlanta, Beijing, Brussels, Charlotte, Dallas, London, Los Angeles, New York, Raleigh, San Francisco, Silicon Valley, and Washington, D.C. Mr. Paul Arena, Chief Executive Officer of Parallax Health Sciences, said, “With Alston & Bird’s assistance, we will identify possible violations of our intellectual property rights and, if appropriate, to initiate legal proceedings.”

Parallax Health Sciences, Inc. (PRLX), closed Thursday's trading session at $0.06, up 25.00%, on 498,081 volume with 18 trades. The average volume for the last 3 months is 218,637 and the stock's 52-week low/high is $0.030999999/$0.165000006.

chart

alpha-En Corporation (ALPE)

Zacks, Stocksbeat, Invest Tribune, Otc.watch, Market Screener, PR Newswire, 4-Traders, Last10k, InvestorsHub, OTC Markets, OilandGas360, Wallet Investor, Morningstar, TradingView, Simply Wall St, and InvestorsHub reported previously on alpha-En Corporation (ALPE), and today we report on the Company, here at the QualityStocks Daily Newsletter.

alpha-En Corporation is an innovative clean technology company based in Yonkers, New York. It concentrates on enabling next generation battery technologies through developing and bringing to market pure, state of the art materials produced in an environmentally sustainable manner. The Company has developed a patent pending process for the production of lithium metal and associated products produced at room temperature. The Company’s first-rate Scientific Team includes a Nobel Prize winning Chemist. alpha-En’s shares trade on the OTC Markets Group’s OTCQB.

alpha-En is enabling next generation energy storage. The Company’s lithium metal is purer than what is currently available on the market. It is free of all base metals and common non-conductive impurities found in the existing commercial supply.

The Company produces its lithium utilizing a room temperature process (process conducted at 20°-30°C) that does not require or release noxious chemicals. Its process allows for the flexible deposition and intercalation of lithium into custom substrates that streamlines the manufacturing of batteries of all sizes.

alpha-En’s novel process is mercury and chlorine free. It eliminates the use and release of toxic chemicals and expensive containment costs. Its electrodeposition method produces thin films of highly pure lithium on a host of substrates. Strategic partners of the Company include Argonne National Laboratory and Princeton University.

In July of this year, alpha-En announced that it received a $1 million technology development grant from the New York State Energy Research and Development Authority (NYSERDA). The funding will help to pay for the substantial amount of research and development (R&D) that is required to bring disruptive battery technology from the laboratory to final commercialization.

Recently, alpha-En announced that it determined that it meets the requirements to be a Qualified Opportunity Business (QOZB) under the Federal Tax Cuts and Jobs Act of 2017 (TCJA). As a QOZB, alpha-En could potentially offer favorable tax treatment to investors in future placements of its securities, as specified in the TCJA. alpha-En's headquarters and laboratory facilities in Yonkers, New York, is located in an Opportunity Zone as certified by the US Treasury under the TCJA.

alpha-En Corporation (ALPE), closed Thursday's trading session at $0.35, up 16.7056%, on 2,150 volume with 3 trades. The average volume for the last 3 months is 4,630 and the stock's 52-week low/high is $0.159999996/$1.29999995.

chart

BioRestorative Therapies, Inc. (BRTX)

Simply Wall St, Capital Cube, Pink Investing, Proactive Investors, 4-Traders, Market Screener, MarketWatch, InvestorsHub, Barchart, Stockopedia, ProActive Capital, GuruFocus, Investor Ideas, Corporate Information, Streetwise Reports, Zacks, Stockhouse, and Marketbeat reported previously on BioRestorative Therapies, Inc. (BRTX), and we also report on the Company, here at the QualityStocks Daily Newsletter.  

BioRestorative Therapies, Inc. is a life sciences company focusing on adult stem cell-based therapies for various personal medical applications. The Company develops products and medical procedures utilizing cell and tissue protocols, primarily involving adult stem cells. OTCQB-listed, BioRestorative Therapies has its corporate, administrative, and laboratory operations in Melville, New York.

The Company’s aim is to become a leader in providing medical procedures using cell and tissue protocols, chiefly involving adult stem cells (non-embryonic), and enabling patients to undergo minimally invasive cellular-based treatments. BioRestorative Therapies is developing a cell-based therapy to target obesity and metabolic disorders utilizing brown adipose (fat) derived stem cells to produce brown adipose tissue (BAT). The intention of BAT is to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. 

Bio Restorative’s lead cell therapy candidate is BRTX 100. This product is formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. The Company’s products and medical procedures include brtxDISC™ (Disc Implanted Stem Cells), its Disc/Spine Program, and ThermoStem®, its Metabolic Program.

brtxDISC™ is an investigational non-surgical treatment for bulging and herniated lumbar discs. brtxDISC™’s intention is for patients who have failed non-invasive procedures and face the prospect of surgery. ThermoStem® is a treatment using brown fat stem cells. ThermoStem® is under development for metabolic disorders, including diabetes and obesity.

BioRestorative Therapies is also the beneficiary of a patent granted for a licensed curved needle device (CND). The design of it is to deliver cells and/or other therapeutic products or material to a site having damage in need of facilitated repair.

Recently, BioRestorative Therapies announced the creation of a Disc Advisory Committee of its Scientific Advisory Board (SAB). Jason Lipetz, MD, a member of the Company’s SAB headed by Dr. Wayne Marasco, will Chair the newly created Committee. Dr. Lipetz joined the SAB in October of 2018.

In addition to Wayne Olan MD, the Director of BioRestorative’s Disc/Spine Regenerative Program, the SAB added Harvinder Sandhu, MD; Christopher Plastaras, MD; and Gerard A. Malanga, MD.

Wayne Marasco, MD, Ph.D., Chairman of the BioRestorative Therapies Scientific Advisory Board, said, "Dr. Jason Lipetz has recruited a prestigious team of spine experts. This SAB subcommittee will provide outstanding leadership and guidance to BRTX as we move toward initiation of our clinical trial for our lead BRTX-100 autologous stem cell product.”

BioRestorative Therapies, Inc. (BRTX), closed Thursday's trading session at $0.0005, up 25.00%, on 35,669,327 volume with 60 trades. The average volume for the last 3 months is 37,413,935 and the stock's 52-week low/high is $0.000199999/$0.910000026.

chart

Innovation Pharmaceuticals, Inc. (IPIX)

Streetwise Reports, Tip Ranks, Insider Financial, Stockopedia, InvestorsHub, Emerging Growth, Stockdigest Report, MarketWatch, Real Investment Advice, Simply Wall St, Stockhouse, The OTC Reporter, Wallet Investor, Investors Hangout, and Barchart reported earlier on Innovation Pharmaceuticals, Inc. (IPIX), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Innovation Pharmaceuticals, Inc. is an OTCQB-listed clinical stage biopharmaceutical company. It is developing unique therapies in manifold diseases. Its belief is that it has a premier portfolio of first-in-class lead drug candidates. The Company is presently advancing them toward market approval, while seeking strategic partnerships. Innovation Pharmaceuticals is headquartered in Beverly, Massachusetts. Innovation is establishing a wholly-owned European subsidiary for the purpose of the development of its drug candidates globally.

The Company’s anti-cancer drug is Kevetrin. It successfully concluded a Phase 1 clinical trial at Harvard Cancer Centers’ Dana Farber Cancer Institute and Beth Israel Deaconess Medical Center. Innovation Pharmaceuticals commenced a Phase 2 study in Ovarian Cancer.

Innovation has its Phase 2 clinical trial with its novel compound Brilacidin-OM for the prevention of OM in patients with head and neck cancer. Brilacidin - a defensin mimetic compound - has shown in an animal model to reduce the occurrence of severe ulcerative Oral Mucositis (OM) by greater than 94 percent versus placebo.

Brilacidin completed a Phase 2b trial for Acute Bacterial Skin and Skin Structure Infection, or ABSSSI. Top-line data have shown a single dose of Brilacidin to deliver comparable clinical outcomes to the Food and Drug Administration (FDA)-approved seven-day dosing regimen of daptomycin.

The Company’s Psoriasis drug candidate is Prurisol. It completed a Phase 2 trial and Innovation launched a Phase 2b study. Prurisol is a small molecule. It acts via immune modulation and PRINS reduction.

This past December, Innovation Pharmaceuticals announced that the Company and the U.S. Food and Drug Administration (FDA) completed an End-of-Phase 2 meeting regarding the continuing development of Brilacidin oral rinse to reduce the incidence of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation. Brilacidin oral rinse is undergoing development under FDA Fast Track designation for Oral Mucositis (OM).

Both parties agreed to an acceptable Brilacidin Phase 3 development pathway. This includes studying Brilacidin oral rinse effects on SOM when cisplatin is administered in higher concentrations (80-100 mg/m2) every 21 days, and at lower concentrations (30-40 mg/m2) administered weekly as part of the chemoradiation regimen.

Recently, Innovation Pharmaceuticals announced plans to initiate this year a clinical trial of Brilacidin as an oral dosage form. Building upon the successful Phase 2 Proof-of-Concept (PoC) clinical trial for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), the goal of the program is to develop treatment for the more extensive forms of Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn’s Disease.

Innovation Pharmaceuticals also recently announced that the Companies Registration Office Ireland provided notification that Innovation’s subsidiary, IPIX Pharma Limited, is registered under the Companies Act 2014, effective February 15, 2019. As Innovation will now be engaging the European Medicines Agency (EMA) to advance its clinical pipeline, the benefits of the subsidiary to the Company will be immediate.

Innovation Pharmaceuticals, Inc. (IPIX), closed Thursday's trading session at $0.10, up 29.0323%, on 2,930,068 volume with 242 trades. The average volume for the last 3 months is 776,003 and the stock's 52-week low/high is $0.05/$0.435099989.

chart

MariMed, Inc. (MRMD)

NetworkNewsWire, CannabisMarketCap, The Cannabis Investor, Pot Stock News, Micro Small Cap, Micro Cap Daily, Insider Financial, Stockhouse, Daily Marijuana Observer, Profit Confidential, Simply Wall St, Proactive Investors, Equity Clock, Stockwatch, Wallet Investor, Trading View, and InvestorsHub reported previously on MariMed, Inc. (MRMD), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed, MariMed, Inc. is one of the largest multi-state cannabis and hemp operators in the U.S. The Company’s dedication is to improving health and wellness with the highest quality hemp and cannabis products. At present, MariMed distributes its branded products in select States. Moreover, the Company is expanding licensing and distribution to many additional markets covering thousands of dispensaries.

MariMed has its corporate office in Norwood, Massachusetts. MariMed announced in late 2018 an investment in Kentucky-based GenCanna, a recognized genetic innovator in industrial hemp.

MariMed offers a complete range of cannabis products and operates state-of-the-art medical and adult-use cannabis dispensaries in six states. In addition, it recently announced the creation of a separate division, MariMed Hemp, centered on the development of industrial hemp-derived CBD products.

The Company is helping build gold standard medical cannabis facilities and programs, one State at a time. It engages in design, development, operation and funding solutions for medical cannabis cultivation centers and dispensaries. The Company’s services include Application Assistance, Real Estate and Safe Access, Build-out and Ongoing Consultation, Business Acceleration Solutions, and Physician and Patient Outreach.

MariMed, across its branded products, including Kalm Fusion™ and Betty’s Eddies™, is at the vanguard of precision dosed branded products for the treatment of specific medical conditions. For dispensaries and cultivation centers already operating, MariMed has a complete set of services to assist in business acceleration, expansion and operational refinement to take the business to the next level.

MariMed has a number of cannabis consulting programs. These include Legal Compliance, Community Outreach, Consensus Building, and Operational Designs. Cannabis consulting programs also include Business Planning and Financial Modeling, Real Estate Selection, Permit Application Preparation, and Systems Design.

Recently, MariMed announced that its MariMed Hemp subsidiary will acquire 70 percent of MediTaurus, LLC. MediTaurus is the owner of the worldwide Florance™ brand of CBD health and wellness products and wide-ranging intellectual property (IP) relating to cannabis formulations.

The Florance™ brand is established in the United States and European Union (EU) with online distributors, wholesalers, pharmacies and physicians. This is the first acquisition for MariMed Hemp, formed to optimize MariMed’s strategic investment in GenCanna Global, Inc., the Kentucky-based producer of compliant, quality CBD derived from hemp.

MariMed, Inc. (MRMD), closed Thursday's trading session at $0.368875, up 22.5498%, on 1,414,877 volume with 345 trades. The average volume for the last 3 months is 601,622 and the stock's 52-week low/high is $0.270999997/$4.19000005.

chart

Integrated BioPharma, Inc. (INBP)

StockMister, OTCPicks, HotShotStocks, Wall Street Mover, Zacks, The Stock Psycho, Top Gun, and AllPennyStocks reported earlier on Integrated BioPharma, Inc. (INBP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Integrated BioPharma, Inc. engages primarily in the manufacture, distribution, marketing, and sales of vitamins, nutritional supplements, and herbal products. Its customers are mainly in the United States, Luxembourg, and Canada. Integrated BioPharma develops, manufactures, and distributes, around the world, in excess of 130 products. The Company does so through several wholly-owned subsidiaries.

Integrated BioPharma formerly went by the name Integrated Health Technologies, Inc. Established in 1979, the Company is based in Hillside, New Jersey. Integrated BioPharma lists on the OTC Markets.

Integrated Biopharma’s companies include AgroLabs, Inc., Chem International, IHT Health Products, Inc., Manhattan Drug Company, and Vitamin Factory. Integrated BioPharma operates via three segments. These are Contract Manufacturing, Branded Proprietary Products, and Other Nutraceutical Businesses.

AgroLabs manufactures and markets healthful nutritional products under the Naturally Noni, Naturally Pomegranate, Naturally Aloe, and Naturally Mangosteen brands. Additionally, AgroLabs distributes internationally, in Canada, Germany, Japan, Korea, Mexico, Taiwan and the United Kingdom (UK). Integrated BioPharma’s Chem International offers a broad assortment of Roche Vitamins' food and cosmetic products.

The Company’s Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. Its Branded Proprietary Products segment distributes healthful nutritional products for sale through mass market, grocery, drug, as well as vitamin retailers.

The Other Nutraceutical Businesses segment sells private label vitamin and nutritional supplement products, and healthful nutritional products through the Internet. In addition, this segment distributes fine natural botanicals. This includes multi minerals and raw materials. Moreover, the Other Nutraceutical Businesses segment provides warehousing and fulfilment services.

Integrated BioPharma’s Vitamin Factory sells nutritional supplements directly to the consumer by way of mail order catalogs and over the Internet. Vitamin Factory’s product categories are dietary supplements, liquid items, sports supplements, and skincare supplements.

Manhattan Drug Company provides vitamins and nutritional formulations. It engages in the manufacturing of tablets, capsules, or blends; packaging and labeling in bulk; help in product registration worldwide, and distribution of finished product. Also, Manhattan Drug Company engages in analytical and microbiological testing via its in-house laboratories.

Integrated Biopharma’s IHT Health Products sells and distributes fine chemicals. These include science-based proprietary products and value added formulations. IHT sells and distributes these to the nutritional, pharmaceutical, food, and cosmetic industries. IHT products include vitamins, amino acids, herbal extracts, Over-the-Counter (OTC) pharmaceuticals, excipients, and unique patented products.

Integrated BioPharma, Inc. (INBP), closed Thursday's trading session at $0.3075, up 33.6957%, on 96,511 volume with 28 trades. The average volume for the last 3 months is 4,682 and the stock's 52-week low/high is $0.1061/$0.310000002.

chart

The QualityStocks Company Corner

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Business-to-business pharmacy services supplier Trxade Group Inc. (OTCQB: TRXD) has remained consistently profitable over the last couple of years, reporting seven consecutive quarters of revenue growth, as it continues to expand its services and reach more patients nationwide, CEO Suren Ajjarapu said in a recent interview with NetworkNewsWire (http://nnw.fm/uCMu0).

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (TRXD), closed Thursday's trading session at $6.5, up 333.3333%, on 469,091 volume with 2,355 trades. The stock's 52-week low/high is $2.0999999/$10.5600004.

Recent News

chart

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE)

The QualityStocks Daily Newsletter would like to spotlight Pacific Rim Cobalt Corp. (OTCQB: PCRCF).

Pacific Rim Cobalt Corp. (CSE: BOLT) (FRANKFURT: NXFE) is pleased to announce a non-brokered private placement for aggregate gross proceeds of $742,164.48. The Company intends to use the net proceeds from the Offering to fund development of its nickel-cobalt business in Indonesia as well as general working capital purposes.

Pacific Rim Cobalt Corp. (CSE: BOLT) (OTCQB: PCRCF) (XFRA: NXFE) is a Canada-based exploration company focused on the acquisition and development of production-grade cobalt deposits, a key raw material input for the growing lithium-ion battery industry.

Pacific Rim Cobalt and its Cyclops Nickel-Cobalt Project, located in the Depapre District, Jayapura Regency, Papua Province, Republic of Indonesia, is uniquely positioned in a region with potentially the largest source of cobalt outside of Africa. Strategically located near China, the world’s largest cobalt buyer, the Cyclops Project is a laterite (iron-hosted) mineral prospect, rich in cobalt and nickel. Cobalt consumption in China is on-track to use over 8,000 tonnes of cobalt annually by 2021 for electric vehicle production alone and is projected to remain the world’s largest cobalt consumer for many years to come.

Global demand for renewable power is fueling a massive shift from traditional energy supply chain economics to cobalt-reliant lithium-ion batteries, the world’s most widely used power source for portable applications such as electric vehicles and other high-tech applications.

Pacific Rim Cobalt management has concluded that strategic access to major markets offers the most important factor to servicing the rising demand for cobalt. The company’s acquisition of its initial asset in Indonesia offers near surface, strong nickel-cobalt mineralization in an area with excellent infrastructure including a nearby workforce, supplies, sealed roads, ocean access, nearby port facility and gentle topography. The project area, nestled on the north coast of Papua, Indonesia, establishes Pacific Rim Cobalt well within the economically attractive ocean-going transportation range to Asia and its lucrative, growing industrial markets.

Exploration efforts are currently focused on establishing a maiden compliant resource for the Cyclops project, both in historically identified and drill-tested prospects as well as previously unexplored areas of the claims. During the first nine months of 2018, the company focused on assembling the necessary agreements to access northern areas of the project hosting historically identified mineralized zones. Mapping, sampling and a mini-bulk sample within the mineralized zones has been completed, along with a small-scale program in the previously unexplored far southern area of the project. With surface access to priority targets now established, Pacific Rim Cobalt will initiate drilling and extract additional mini-bulk samples for further metallurgical testing.

“We are excited and optimistic about the unique possibility of developing this project into an asset that will add shareholder value and position the company to play a future role in the battery metals supply chain,” Pacific Rim Cobalt CEO Ranjeet Sundher recently stated (http://nnw.fm/u1HNs). “We expect the near-surface nature of cobalt/nickel mineralization at the Cyclops project will lend itself well to low-cost, logistically straightforward drilling. We thus anticipate the opportunity to undertake a resource calculation study, as well as ongoing metallurgy and process option testing, will present itself in the near future. It’s going to be a busy year ahead, and we look forward to getting the drills turning and building value.”

Pacific Rim Cobalt’s world-class management team includes Sundher, who has over 20 years of capital markets experience. Sundher is also president of Canrim Ventures Ltd., a Singaporean advisory firm specializing in early stage project finance and structure. He previously founded Indogold Exploration, a Jakarta-based mining service firm, and has raised over $40 million for companies in which he was a founder/partner.

Chief Financial Officer Steve Vanry has 25 years of professional experience in senior management positions with public and private natural resources companies, providing expertise in capital markets corporate finance, mergers and acquisitions, regulatory compliance, accounting and financial reporting.

Andre Talaska serves as country manager and technical supervisor. He has over 30 years of experience in the mining and exploration industry and has held senior positions with several companies in Australia and southeast Asia. Shakir Juffry, business development/engineering, is a chemical engineer and extractive metallurgist by background training who has over 20 years of experience in the Indonesian mining and minerals exploration field. Toto Suarto Sajali, operation and development manager, is a mining engineer with over 15 years of experience in Indonesian project assessment, development and operations.

Pacific Rim Cobalt Corp. (OTCQB: PCRCF), closed Thursday's trading session at $0.1676, up 8.4088%, on 13,212 volume with 8 trades. The average volume for the last 3 months is 18,996 and the stock's 52-week low/high is $0.079999998/$0.259299993.

Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

SRAX (NASDAQ: SRAX), a digital marketing and consumer data management technology company, this morning released results from its BIGresearch study. The study of over 53,000 Americans was conducted in January 2020 and the results uncover this year's Valentine's Day consumer behaviors and opinions. Among other highlights, the study found that 79% of people celebrating this year are between the ages of 18 and 34, with 47% between 25 and 34. To download the full Valentine's Day 2020 Report, visit http://nnw.fm/4TqxQ. To view the full press release, visit http://nnw.fm/A2gPN. Also today, NetworkNewsWire released a report on the company detailing how SRAX has developed a consumer-managed data marketplace that delivers a digital competitive advantage for brands. Through its exclusive platform BIGtoken, SRAX provides everyone in the Internet ecosystem choice with transparency and compensation. Consumers who use BIGtoken are able to own and monetize their data while brands that purchase access to that data benefit from higher ROIs.

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Thursday's trading session at $2.4221, up 8.6143%, on 76,170 volume with 224 trades. The average volume for the last 3 months is 105,780 and the stock's 52-week low/high is $1.04999995/$5.8499999.

Recent News

chart

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs Inc. (NASDAQ: SGLB), a leading developer of quality-assurance software for the commercial 3D-printing industry, is steadily strengthening its position in the burgeoning additive marketing (AM), or 3D metal printing, space. While forecast numbers vary, a recent “Barron’s” article quotes an industry expert predicting consistent 35% annual growth in the specialized market for the foreseeable future (http://nnw.fm/g9Dw1). That growth, said the article, comes as 3D metal printing technology partnered with artificial intelligence offers significant benefits in a wide range of verticals. With its unmatched quality control technology, SGLB appears positioned at the vanguard of an industry poised for explosive growth.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Thursday's trading session at $0.9726, up 2.3789%, on 61,934 volume with 132 trades. The average volume for the last 3 months is 102,941 and the stock's 52-week low/high is $0.451099991/$2.45000004.

Recent News

chart

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF).

Hemp biomass cultivation, extraction, formulation and refining entity HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) is slated for market growth through 2020 as the U.S. hemp-based, CBD-products market continues to flourish. A recent article discussing the company reads, “Overall, HTC Extraction Systems has a highly optimistic outlook when it comes to its extraction market expansion, where it is already a key player. The company expects a wealth of opportunities for growth in the near future, given the rapid expansion of the cannabinoid market as a whole. To view the full article, visit http://cnw.fm/j1jgS

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

  • LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
  • PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
  • Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

  • Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
  • Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
  • Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (OTCQB: HTPRF), closed Thursday's trading session at $0.145, up 3.5714%, on 5,500 volume with 2 trades. The average volume for the last 3 months is 2,854 and the stock's 52-week low/high is $0.100299999/$0.920000016.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint Inc. (OTCQB: SING) acquired Direct Solar America, which is a unique and scalable national solar energy brokerage. Focused on finding and arranging installation of the best available solar energy system for any residential home or commercial building. In a little over six months since the acquisition revenues and coverage has expanded, firmly establishing the company’s footprint in the solar sector, which is predicted to continue growing throughout the next decade. Also today, NetworkNewsWire released a report on the company detailing how SING provided today an update on the bullish outlook for 2020 and beyond, for solar and renewable energy and its acquisition of Direct Solar America, a unique and scalable national solar energy brokerage focused on finding and arranging installation of the best available solar energy system for any residential home or commercial building. To view the full press release, visit http://nnw.fm/0kI5h.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Thursday's trading session at $0.011, up 20.2186%, on 10,246,675 volume with 363 trades. The average volume for the last 3 months is 3,419,604 and the stock's 52-week low/high is $0.007/$0.023.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Global innovators in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will provide its patented DehydraTECH(TM) technology to Cannadips Cannabis for use on the latter’s market in California and nationwide according to a new definitive agreement. Currently, Cannadips Cannabis Tins are sold in California. Each tin contains 15 pouches with 10 mg of tetrahydrocannabinol each, no nicotine, no tobacco, and all-natural sweeteners. The company also has a high-dose version with 15 pouches and 20 mg of cannabis-derived THC each (http://cnw.fm/7V8qe). Also today, the company was highlighted in a publication from CBDWire, examining how LXRP will provide its patented DehydraTECH(TM) technology to Cannadips Cannabis for use on the latter’s market in California and nationwide according to a new definitive agreement. Currently, Cannadips Cannabis Tins are sold in California. Each tin contains 15 pouches with 10 mg of tetrahydrocannabinol each, no nicotine, no tobacco, and all-natural sweeteners. The company also has a high-dose version with 15 pouches and 20 mg of cannabis-derived THC each (http://cnw.fm/7V8qe ).

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Thursday's trading session at $0.4975, off by 2.0091%, on 31,038 volume with 38 trades. The average volume for the last 3 months is 104,711 and the stock's 52-week low/high is $0.3037/$1.57000005.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com (OTCQB: CIIX), a financial news media and content platform that provides information to the global Chinese-speaking community, plans to expand its customer base with new hemp-based CBD products in 2020. Through CIIX’s CBD Biotech subsidiary, CEO Warren Wang plans to capitalize on the massive potential of the untapped Chinese CBD market. To view the full article, visit http://cnw.fm/A54xC.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Thursday's trading session at $0.14, off by 11.3924%, on 261,914 volume with 19 trades. The average volume for the last 3 months is 51,777 and the stock's 52-week low/high is $0.119999997/$0.51999998.

Recent News

chart

Youngevity International, Inc. (NASDAQ: YGYI)

The QualityStocks Daily Newsletter would like to spotlight Youngevity International, Inc. (YGYI).

Youngevity International (NASDAQ: YGYI), a multi-channel lifestyle company operating in three distinct business segments, including a commercial coffee enterprise and its newly acquired commercial hemp enterprise, today announced the reshaping of its Board of Directors. According to the update, effective February 11, 2020, in order to maintain compliance with The Nasdaq Capital Market’s corporate governance requirements and, specifically, Listing Rule 5605(b) which provides that a listed company's board of directors shall be comprised of a majority of independent directors, Michelle Wallach and Richard Renton, two non-independent members of the Board of Directors of YGYI resigned as members of the Board of Directors of the company. To view the full press release, visit http://cnw.fm/t3Z9d

Youngevity International, Inc. (NASDAQ: YGYI) is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model that includes e-commerce and the power of social selling. Among the Top 100 Global Direct Selling Companies, Youngevity offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, and a range of innovative services. Created through the 2011 merger of Youngevity Essential Life Sciences with Javalution® Coffee Company, today’s Youngevity International Inc. is a virtual worldwide Main Street of products and services under one corporate entity that supports a healthy and empowered lifestyle.

Youngevity International is dedicated to improving lifestyles through the universal desires of vibrant health and flourishing economics. Catering to health-conscious consumers, Youngevity believes that combining the best of the direct selling industry with the fundamentals and capabilities of a traditional business model will maximize shareholder value. The company’s Nutritional, Lifestyle and Telecommunications products and services are distributed through a global network of Preferred Customers and Distributors.

Youngevity’s wholly owned CLR Roasters LLC business line offers quality branded and private label coffee to retail stores, office coffee services, hospitality, food services, distributors, convenience, petrol stores and vending businesses. Today, CLR Roasters is the largest coffee provider for cruise lines in North America and the second largest roaster in the state of Florida. Producing a consistent premium product with superior taste, CLR Roasters has earned numerous certifications that demonstrate the company’s commitment to the craft of providing the highest quality coffee products using the best practice standards available.

Youngevity, operating in the direct-selling channel, is rapidly expanding its product and distributor base through acquisitions and mergers under an innovative concept called “the Network Cloud” that provides other direct selling companies with a home base. The company’s YoungevityGO2 mobile distributor app, a new technology-driven web platform supporting expansion of global e-commerce and social selling platforms, is available on Google Play and the App Store. In addition to the Network Cloud concept, Youngevity International owns CLR Coffee Roasters which operates a traditional coffee roasting business offering a JavaFit® gourmet product line that vertically integrates with Youngevity and its growing network of direct marketers.

Youngevity International offers more than 1,000 high quality, technologically advanced products under the following categories:

  • Health and Nutrition
  • Home and Family
  • Food and Beverage
  • Spa and Beauty
  • Fashion
  • Essential Oils
  • Photo and scrapbooking
  • Services for Home and Business

Youngevity International Inc. has compiled a best-in-class management team with a strong track record of success in private and public companies. Steve Wallach, CEO, has nearly two decades of sales and network marketing experience and has successfully guided Youngevity International Inc. to become an international, publicly-traded direct marketing company positioned for worldwide growth. Dave Briskie, president and CFO, has shepherded the company’s development into a fully vertical coffee roasting and distribution company that owns the direct marketing brand JavaFit® and the retail brand, Café La Rica.

Youngevity has also attracted a stunning group of Brand Evangelists who endorse its products. Among these are actress, author and well-known health and wellness activist Marilu Henner; former NBA basket player, Mike “Stinger” Glenn; former NFL wide receiver Drew Pearson; “Greatest Natural Bodybuilder in the World” Gene Nelson; and WNBA champion, Olympic gold medalist Delisha Jones.

Youngevity International, Inc. (NASDAQ: YGYI), closed Thursday's trading session at $1.44, up 2.8571%, on 127,271 volume with 546 trades. The average volume for the last 3 months is 82,198 and the stock's 52-week low/high is $1.30999994/$8.36999988.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company, Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced its financial and operating results for the three and six months ended December 31, 2019, as well as an update on its strategy and outlook. As announced on February 11, 2020, Supreme Cannabis has implemented a new operating structure, including staff reductions, to drive efficiencies and support long-term, profitable growth. With an optimized cost structure in place, the Company is moving forward with its strategy to transition to a premium cannabis CPG company, driving near-term revenue with new high-quality brands and products at every price segment.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees and culture of innovation. The company aims to grow the world’s best legal cannabis and become a leader in the global industry. Supreme Cannabis calls its Toronto Venture Exchange stock symbol, “FIRE,” a testament to the company’s passion for cannabis and obsession with quality.

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as one of Canada’s most premium cannabis producers, the company sees itself at the center of this global shift.

A key piece of Supreme Cannabis’ ability to fulfill its mission is its flagship brand, 7ACRES, a wholly owned subsidiary that operates a 440,000-square-foot hybrid cultivation facility in Kincardine, Ontario. 7ACRES is focused on building a core competency in scaled high-quality cannabis production. With a best-in-class cultivation facility producing a competitive product that fuels a leading premium brand, Supreme Cannabis has achieved a differentiated advantage in cultivation IP, products and branding. The company’s foundational investment in premium cultivation has secured it a leadership position in the industry as the Canadian market becomes more competitive and matures.

Since legalization, 7ACRES has brought five premium flower strains to market in Canada. The demand for 7ACRES product continues with the company’s most recent launch of Jack Haze, a new proprietary premium cultivar. The company’s first sativa-dominant strain, Jack Haze offers rare sensory characteristics, delivering high THC content with a terpinolene forward profile, including a complex aroma with notes of citrus, pine and warm spice. As it develops its next winning strain, 7ACRES continues to prioritize subjective quality. In the Canadian cannabis market, this approach has established 7ACRES as a well-known premium brand that commands premium pricing coast-to-coast.

In addition to 7ACRES, Supreme Cannabis has built a diversified portfolio of focused consumer-driven brands:

  • Sugarleaf by 7AC – this new brand widens Supreme Cannabis’ product offerings and targets consumers who are looking for more refined, milder consumption experience as they discover their own cannabis taste preferences and desires. Product formats under this brand are focused on offering consumers elegant and convenient cannabis experiences.
  • Blissco — dedicated to providing wellness focused consumers with premium cannabis products, education, and outstanding customer care. Blissco is focused on bringing its collection of premium whole-flower CBD oils to market.
  • Truverra — focused on being a global leader in the development, production and marketing of hemp and cannabis-derived medicinal products with clinically proven efficacy. With over 25 SKUs sold online in the UK and Europe, Truverra is ideally positioned to address emerging international cannabis opportunities.
  • Khalifa Kush Enterprises — formed through a prestigious international partnership with Khalifa Kush Enterprises (KKE) Canada, the Canadian counterpart to the popular U.S. cannabis brand KKE formed by Wiz Khalifa. Together, Supreme Cannabis and KKE Canada are developing and launching a lineup of premium cannabis products, including a future line based on the well-known Khalifa Kush strain.

Each of Supreme Cannabs’ brands and partnerships have been strategically identified and designed to support the company’s mission to enhance the lives of consumers through positive cannabis experiences. Equally important to delivering desirable consumer experiences is the infrastructure supporting the company’s brands and products. From seed to sale, supreme cannabis continues to build an impressive group of operating assets that serve key functions throughout the value chain:

  • Cultivation – for starters, there is Supreme Cannabis’ foundational flagship asset, its 440,000-square-foot cultivation facility in Kincardine, Ontario. With over 600 employees, 24 grow rooms, and best-in-class processing equipment and procedures, this facility is expected to reach an annual production capacity of 50,000 kilograms in the near-term. In this purpose-built facility, the company grows small-batch high-quality cannabis from 10,000-square-foot grow rooms and completes a proprietary hang-dry for up to two weeks.
  • Extraction – with the acquisition of Blissco in fiscal 2019, in addition to the Blissco wellness brand, Supreme Cannabis gained a 12,000-square-foot dedicated extraction facility in Langley, BC. This facility conducts both C02 and ethanol extraction and with the recent receipt of its oil sales license from Health Canada, it now produces Blissco branded CBD oils and expects to fill vaporizer pods for a partnership between the company’s 7ACRES brand and Pax Labs.
  • Manufacturing – most recently, the company announced its 107,000-square-foot processing, packaging and manufacturing facility in Kitchener, naming the facility Supreme Cannabis Kitchener. In Q4 FY2020, the company expects to begin whole flower packaging and pre-roll manufacturing for Supreme Cannabis brands at the Kitchener Facility. In the long-term, in additional to processing its own inputs, Supreme Cannabis intends generate incremental revenue by packaging, distributing and branding third-party cannabis inputs from quality-focused cultivators.
  • R&D and Product Testing – In Q1 FY2020, Supreme Cannabis closed the acquisition of Truverra and acquired a 5,000-square-foot facility licensed under Canadian Clinical Cannabinoids Inc. in Scarborough, Ontario (“Supreme Cannabis Scarborough”). Supreme Cannabis Scarborough provides R&D space for the company to test new products and develop medicinal science intellectual property. In the near-term, with the legalization of 2.0 cannabis products, this centre for innovation will be testing and bringing concentrate products to market under the 7ACRES brand.

Supreme is committed to continue to identify new opportunities to grow and strengthen its impressive portfolio of operating assets and brands and scale its strong Canadian business globally.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Thursday's trading session at $0.30847, up 1.1377%, on 1,134,206 volume with 438 trades. The average volume for the last 3 months is 488,422 and the stock's 52-week low/high is $0.294999986/$1.75.

Recent News

chart

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF)

The QualityStocks Daily Newsletter would like to spotlight Siyata Mobile Inc. (SYATF).

Siyata Mobile (TSX.V: SIM) (OTCQX: SYATF) this morning reported that it has signed a multi-year supply agreement with a global land mobile radio (“LMR”) and software vendor. Per the agreement, Siyata Mobile will supply the Uniden(R) UV350 in-vehicle IoT device to the vendor for resale to first responder and commercial fleet customers wanting to improve their current in-vehicle communication hardware with next generation IoT solutions. To view the full press release, visit http://nnw.fm/ex7uD

Siyata Mobile Inc. (TSX.V: SIM) (OTCQX: SYATF) is a leading global developer and provider of Push-to-Talk Over Cellular ("PTT/PoC") systems for enterprise customers. The company specializes in connected vehicle products for professional fleets and markets its products under the Uniden® Cellular brand.

Since its inception in 2012, Siyata has amassed a customer base that includes cellular operators, commercial vehicle technology distributors, and fleets of all sizes in Canada, the U.S., Europe, Australia and the Middle East.

Recognized by the Toronto Venture Stock Exchange in 2018 as a Venture Top 50 Company, Siyata aims to deliver the highest quality and most technologically advanced mobile communication devices for global corporate workforces, fleets, homes and buildings.

The company has long been an industry pioneer, delivering the world's first 3G connected vehicle device as well as the world's first 4G/LTE vehicle mounted smartphone for First Responders and commercial fleets and vehicles.

Siyata is headquartered in Montréal, Québec, Canada.

Product Portfolio

Siyata's suite of technology includes numerous PTT and legacy devices, as well as cellular boosters designed to improve cellular signals in corporate warehouses, government embassies, retirement home campuses, banks and manufacturing plants.

The company's flagship product, the Uniden UV350, is the world's first vehicle-mounted 4G/LTE smartphone with crystal clear quality, carrier grade PTT, voice, text, video and data applications built into a single device. Specifically designed for First Responder and commercial fleet vehicles, the UV350 runs on cellular LTE networks that provide nationwide and global coverage, replacing traditional single purpose two-way radios that require a monthly fee and limited network coverage.

The Uniden UV350 is currently available through Bell Mobility, Canada's largest LTE network and PTT community. Expanding its availability, Siyata is completing network approval with two North American Tier 1 operators to launch the UV350 in the U.S. in 2019.

Management Team

CEO and Chairman Marc Seelenfreund is the founder of Siyata. He is also the founder of Siyata's parent company, Accel Telecom, an Israel-based company that specializes in importing and distributing innovative cellular and IP devices to fixed line operators and mobile providers within Israel. Prior to establishing Accel, Seelenfreund was a vice president at Sunrise Corporation in New York where he focused on financing publicly traded technology companies. Seelenfreund has a law degree from Bar Ilan University, is a board member at Israel's leading private university, and has served as an officer in the Israel Defense Forces.

Glenn Kennedy, vice president of sales, has over 25 years of sales experience in the telecommunications industry. Prior to joining Siyata in 2016, Kennedy managed sales nationally for Motorola Canada, HTC Communications Canada, and Sonim Technologies. He holds a bachelor's degree in honors business administration from the Richard Ivey School of Business at the University of Western Ontario.

CFO Gerald Bernstein, a professional chartered accountant, has spent 20 years focusing on private equity financing and tax efficient corporate structuring in multi-jurisdictional arenas. He holds a bachelor's degree of commerce as well as a graduate diploma in public accountancy from McGill University. Bernstein has been a member of the Canadian Institute of Chartered Accountants since 1987.

Gidi Bracha, Vice President of Technology, has served in this position since 2011 and spearheaded the development of both the Truckfone, Voyager and UV350. Bracha served in various key positions at Cellcom, Israel's leading cellular provider, including head of car mobility products and director of type approvals. Bracha served as an engineer technician in the Anti-Aircraft division of the Air Force in the Israel Defense Forces and holds a bachelor's degree in engineering and business management from the University of Derby.

Siyata Mobile Inc. (SYATF), closed Thursday's trading session at $0.2207, up 6.9978%, on 122,376 volume with 38 trades. The average volume for the last 3 months is 94,751 and the stock's 52-week low/high is $0.198500007/$0.446249991.

Recent News

chart

CloudCommerce (OTCQB: CLWD)

The QualityStocks Daily Newsletter would like to spotlight CloudCommerce (OTCQB: CLWD).

CloudCommerce (OTC: CLWD), a leading provider of digital advertising solutions, today announced receipt of its first subscriptions in its $20 million Reg A+ Public Offering. According to the update, CloudCommerce is offering up to $20,000,000 of preferred stock, at a price of $25.00 per share, to qualified investors in a Reg A+ public offering. The preferred stock will pay a 10%, annual dividend, with payments made monthly. CloudCommerce will seek to have a market maker file an application with FINRA in order to quote the Preferred Stock on the OTC market. To view the full press release, visit http://nnw.fm/CepJ8.

CloudCommerce (OTCQB: CLWD) is a leading provider of audience-driven business intelligence and marketing solutions. Together with its wholly owned subsidiaries, CloudCommerce delivers invaluable end-to-end business intelligence and marketing solutions through a range of services and capabilities.

Flagship Solution

SWARM is an end-to-end solution that applies advanced data science, behavioral science, artificial intelligence and market research techniques to deliver powerful audience-driven business intelligence that converts opportunities into business success.

Through marketing, brand perception, customer-relationship management, human-resources management and operational logistics applications, CloudCommerce’s SWARM solution helps businesses determine who to talk to, what to say and how to motivate targeted audiences to take meaningful action.

The Market

Marketers have largely taken a blanket approach to communication. The same messages are often sent across an entire customer audience with little regard for how different groups of people communicate, build communities and develop their purchasing habits. When marketers do segment audiences, they use objective selection criteria such as income, geography, education or purchase history to deduce attitudes or intentions.

However, research shows that motivations and feelings are much more accurate at predicting behavior. The challenge for businesses is that these factors are also the hardest to gather from audience data. CloudCommerce provides that audience-intelligent data through SWARM, its proprietary behavioral-science approach to audience creation and communication. Through SWARM, CloudCommerce helps marketers identify consumer motivations and triggers in order to effectively predict and influence actions. When companies influence action, they can change opinions, gather support, motivate purchases and inspire change.

In a fast-developing global business intelligence market estimated to grow from $16.3 billion in 2016 to $34.3 billion by 2022, CloudCommerce stands apart as an innovator and true partner, able to deliver data-driven intelligence and solutions that enable its customers to strengthen their brands, deliver their messages and reach their goals.

SWARM Products

THE SWARM—Intelligent Audience Building
The core of the CloudCommerce solution – and what separates CloudCommerce from other audience data companies – is the company’s unique approach to audience building. The concept of “personas” has been around for decades, but CloudCommerce takes that concept to the next level. The SWARM was developed to identify not only who to talk to but also what to say in order to motivate target audiences to take meaningful action. Using CloudCommerce’s proprietary clustering and behavioral analysis techniques, businesses can identify target audiences and deliver messages that are more focused and efficient. CloudCommerce not only helps its client partners find the right people to talk to but also identifies the most powerful message to send.

BUZZ—Behavior-Based Market Research
Market research is evolving. Research techniques developed and used today are more sophisticated and backed by strong data science. Despite these changes, many traditional research firms have failed to innovate: small sample sizes, survey design bias, improper weighting and gut-intuition sampling are just some of the issues that plague the market-research industry. Through BUZZ, CloudCommerce has automated the market research process to provide a level of statistical depth beyond what traditional firms can offer. BUZZ offers businesses the ability to put their finger on the pulse of the marketplace in the moment. Using a wide range of internal and external data sources such as customer data, social media activity, and micro and macro trends, BUZZ deduces attitudes, emotions and opinions.

HIVE—Redefined Geographic Targeting
Conventional geographic audience targeting is outdated. Arbitrary units of location such as counties, cities, DMAs and regions were created centuries ago based on land-rights ownership. Their use in understanding people’s behavior, purchase habits and underlying values is minimal. CloudCommerce has found a much more powerful, efficient and effective way of targeting by clustering people into granular geographic tribes called HIVES. HIVES are defined by attributes such as common language (e.g., colloquialisms), shared experience and narratives (e.g., climate, history), and concentrated demography and biology (e.g., ethnicity, age). Based on the needs of its clients, CloudCommerce can completely redraw the geographic lines based on various Hive selection criteria. Using this exclusive HIVE approach, CloudCommerce clients experience more efficient and effective marketing, make more intelligent business decisions and enjoy more growth.

HONEY—Advanced Reporting and Visualization
Advanced-audience, data-analysis technologies are useless if they don’t produce simple, powerful and actionable business intelligence. HONEY comes with user-friendly reporting and visualization tools to organize and explain all of the advance-data science into a simple-to-understand format for decision makers. HONEY combines the intelligence of client CRM data with third-party consumer data and targeted market research to create a powerful foundation for any audience-intelligence solution.

Subsidiaries

Data Propria
Data Propria delivers the highest Return on Investment (“ROI”) for their customers’ digital marketing campaigns, by utilizing sophisticated data science to identify the correct universes to target relevant audiences. Their ability to understand and translate data drives every decision they make. By listening to and analyzing their customers’ data they are able to make informed decisions that positively impact their customers’ business. Data Propria leverages industry-best tools to aggregate and visualize data across multiple sources, and then their data and behavioral scientists segment and model that data to be deployed in targeted marketing campaigns. They have data analytics expertise in retail, wholesale, distribution, logistics, manufacturing, political, and several other industries.

Parscale Digital
Parscale Digital helps their customers get their message out, educate their market and tell their story. They do so creatively and effectively by deploying powerful call-to-action digital campaigns with national reach and boosting exposure and validation with coordinated advertising in print media. Parscale Digital’s fully-developed marketing plans are founded on sound research methodologies, brand audits and exploration of the competitive landscape. Whether their customer is a challenger brand, a political candidate, or a well-known household name, Parscale Digital’s strategists are skilled at leveraging data and creating campaigns that move people to make decisions.

Giles Design Bureau
Giles Design Bureau approaches branding from a “big picture” perspective, establishing a strong identity and then building on that to develop a comprehensive branding program that tells the customer’s story, and articulates what sets the customer apart from their competitors and establishes the customer in their market.

WebTegrity
WebTegrity develops commerce-focused, user-friendly digital websites and apps that elevate their customer’s marketing position and draw consumers to their products and services. Their platform-agnostic approach allows WebTegrity to architect and build solutions that are the best fit for each customer. Once the digital properties are built, their experts will help manage and protect the website or app and provide the expertise needed to scale the infrastructure needed as the customer’s business grows.

Leadership

Andrew Van Noy, CEO & Chairman of CloudCommerce Board of Directors
Andrew Van Noy has been a director of CloudCommerce since November 2012, president of the company since April 2012, and the CEO of the company since August 2012. He also served as executive vice president of CloudCommerce from November 2011 to April 2012 and vice president of Sales and Marketing of the company from May 2011 to November 2011. From January 2009 to April 2011, Van Noy served as the vice president of Sales and Marketing for PageTransformer, which provided web and software development for iPad, iPhone and Android devices. Van Noy came to CloudCommerce with experience in digital marketing, private equity and investment banking. During his years at the company, Van Noy led the efforts to rebrand and restructure the business and presided over the acquisition of a number of companies. Van Noy graduated from BYU with a Bachelor of Science degree.

Gregory Boden, CFO and Board of Directors
Gregory Boden became a director at CloudCommerce in November 2011 and in February 2013 was named corporate secretary. In April 2012, Boden was also appointed CFO. In addition, Boden is the managing partner of a private equity company. Prior to joining the CloudCommerce team, Boden managed the franchise accounting and cash application departments of Select Staffing, a nationwide staffing company and was an accountant at KPMG LLP. Boden earned his master of accountancy degree from the University of Denver.

CloudCommerce (OTCQB: CLWD), closed Thursday's trading session at $0.004, up 2.5641%, on 17,424,300 volume with 201 trades. The average volume for the last 3 months is 23,800,046 and the stock's 52-week low/high is $0.001399999/$0.0228.

Recent News

chart

Endonovo Therapeutics Inc. (ENDV)

The QualityStocks Daily Newsletter would like to spotlight Endonovo Therapeutics Inc. (ENDV).

Endonovo Therapeutics (OTCQB: ENDV) today announced its collaboration with a Stanford University sponsored Orthopedic Shoulder and Knee Study to determine benefits of Endonovo's tPEMF SofPulse(R) on pain, medication levels and physical function post-operatively. According to the update, the study will evaluate 76 patients with Active and Sham Comparator groups, measured by visual analog scale (“VAS”), at 10 days after, and will allow surgeons to determine postoperative efficacy of Endonovo's SofPulse(R) tPEMF portable device. To view the full press release, visit http://nnw.fm/CI0d0

Endonovo Therapeutics Inc. (ENDV) develops, manufactures and distributes evolutionary medical devices focused on the rapid healing of wounds and reduction of pain, edema and inflammation on and in the human body. These wearable, non-invasive medical devices are designed to deliver the company’s proprietary, patent protected Electroceutical™ Therapy targeting inflammation, cardiovascular diseases, chronic kidney disease and central nervous system (“CNS”) disorders.

In accord with its mission to transform the field of medicine through innovation, Endonovo’s bioelectric Electroceutical™ devices harness bioelectricity to restore key electrochemical processes that initiate anti-inflammatory processes and growth factors in the body necessary for healing to rapidly occur. Endonovo’s current portfolio of commercial-stage devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke.

Flagship Therapy

SofPulse® Electroceutical ™ Therapy is an easy-to-place, non-invasive device that delivers pulsed electromagnetic frequencies to enhance post-surgical recovery. Used as a stand-alone therapy or integrated into any treatment protocol, SofPulse®’s targeted pulsed electromagnetic field (tPEMF) transmits gentle pulses to the tissue causing a positive biological effect to help reduce swelling and accelerate the body’s natural recovery process. The low levels of electromagnetic fields are completely safe and are 1000 times lower than those emitted by a mobile phone. 

Because SofPulse® lessens the pain of post-surgical recovery, the patient requires far less prescription medications, thereby minimizing or eliminating the adverse side effects of narcotics and anti-inflammatory medication. Studies have shown a greater than 2.2-fold reduction in narcotic use over the first 48 hours post-procedure. Patients with less pain and medication may move around sooner, which further stimulates the body’s natural response to healing.

Certifications

Endonovo’s Electroceutical™ Therapy is cleared by the U.S. Federal Drug Administration (“FDA”) for the palliative treatment of pain and post-surgical edema (swelling) and is CE-marked in the European Economic Area (“EEA”) for the promotion of wound healing and the palliative treatment of pain and post-surgical edema. The Centers for Medicare and Medicaid Services (“CMS”) has also certified Electroceutical™ Therapy for the treatment of chronic wounds.

Management

Alan Collier, Chairman and CEO
Alan Collier has more than 25 years of experience in corporate finance, IP development, telecommunications and technology, with a concentration in healthcare and technology over the past five years. Collier has served as CEO and director of IP Resources International Inc., where he was instrumental in developing a platform the for the licensing and acquisition of life science and technology companies. He has held numerous board and executive positions throughout his career in the telecommunications, technology, specialty finance, corporate finance and healthcare industries. Collier has previously held FINRA Series 7, 79, 63 and 24 licenses.

Michael Scott Mann, President
Michael Scott Mann has over 30 years of experience in merger and acquisitions and operational management. In 2008, Mann acquired the assets of Hanover Asset Management, now Endonovo Therapeutics Inc., and led the company to become listed on the OTCBB in 2012. He was the founder, president and CEO of Frankfurt-listed U.S. Debt Settlement Inc. (USDS), where he implemented a growth by acquisition strategy. 

Don Calabria, Chief Operating Officer
Don Calabria has over 20 years of leadership and experience in national business operations to emerging growth companies, mergers and acquisitions, finance and business development. Calabria holds an MBA from the Graziadio School of Business and Management at Pepperdine University and a bachelor’s degree from Arizona State University.

Nevena Zubcevik, Chief Medical Officer
Nevena Zubcevik, D.O., MSPT, ATC, on July 1, 2019, will lead Endonovo’s medical and clinical strategy, including the development and regulatory matters and new business development. Zubcevik, a licensed physician and educator, has more than 24 years of experience in the medical field and was an attending physician at Harvard Medical School/Partners Healthcare in the physical medicine and rehabilitation department.

Steven Ford, Vice President of Marketing
Steven Ford has 25 years of experience in the field of medical devices, including experience in sales management, product management, product development, business development and research & development at companies such as Baxter, CR Bard, Ethicon, Allergan, Mallinckrodt Pharmaceuticals and Alphatec Spine. Throughout Ford’s career, he has led and participated on over 75 product development teams and has launched over 50 medical devices globally. Ford is an innovative problem solver and has many patents in the areas of hemostasis, sealing and tissue reconstruction. Most recently, Steve was the U.S. vice president of marketing for Biom’up where he was a co-lead on the high-profile successful launch of their surgical hemostat HEMOBLAST Bellows. Steve holds a bachelor’s degree in marketing from California State University.

David Clark, Vice President of Sales
David Clark has extensive surgical device commercial experience which includes 25 years in the surgical device industry with leading companies including Medtronic and Baxter Healthcare. Most recently, Clark was the U.S. executive vice president of sales for Biom’up where he was a co-lead in the high-profile successful launch of their surgical hemostat HEMOBLAST. As part of the launch, he built and led the U.S. sales team which included over 200 in-direct sales representatives and direct commercial leadership. During his 15 years with Baxter, the BioSurgery Division grew from a small revenue business into a major market player in the advanced hemostasis space with products such as FloSeal and Tisseel. Clark has a bachelor’s degree in economics from Rutgers University.

Roc Alan McCarthy, Scientific Advisory Board Member
Roc Alan McCarthy, D.O, will help Endonovo continue to advance its clinical pipeline and contribute to the strategic and clinical development oversight of the company. McCarthy is a urologist in North Carolina, currently serving as the robotic surgeon and chairman of the robotics committee at the New Hanover Regional Medical Center.

Steven C. Levin, M.D., Scientific Advisory Board Member
Dr. Steven C. Levin is the regional medical director at Johns Hopkins School of Medicine and medical director at Howard County General Hospital in Columbia, Maryland. Additionally, he is an assistant professor at Johns Hopkins School of Medicine, Department of Anesthesiology. Dr. Levin is currently the co-chair of the Opioid Stewardship Clinical Community as well as a clinical design team leader of the Musculoskeletal Center in the Johns Hopkins Health System. Additionally, Dr. Levin has previously served on the medical school facility at Yale University and at University of Pittsburgh Medical Center. Dr. Levin received his undergraduate degree from University of Pennsylvania and medical degree at the University of Pittsburgh. He completed his residency and fellowship at the University of Pittsburgh Medical Center. His membership in professional and scientific societies has included the American Society of Anesthesiology, American Pain Society, American Society of Regional Anesthesia, Society in Anesthesia and International Association for the Study of Pain.

Peter Novak, M.D., Ph.D., Scientific Advisory Board Member
Dr. Peter Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist. He is a member of the American Academy of Neurology, American Autonomic Society and the Autonomic Board of United Council for Neurologic Subspecialties. Dr. Novak graduated from medical school in Bratislava, Slovakia, and completed his neurology residency at Ohio State University. He also completed postdoctoral studies focusing on cardiovascular and autonomic research at Charles University (Prague) the University of Montreal, McGill University (Montreal) and the Mayo Clinic. He has special interests in autoimmune, small fiber and autonomic neuropathies, autoimmune, postural orthostatic tachycardia syndrome and multiple system atrophy. He has written over 70 papers and presented at numerous conferences.

Geoffrey Abrams, M.D., Scientific Advisory Board Member
Dr. Geoffrey Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine and the director of sports medicine for Stanford’s varsity athletes. He specializes in orthopedic sports medicine and arthroscopy of the shoulder, knee and elbow as well as upper extremity joint replacement surgery. Dr. Abrams is a member of the American Academy of Orthopedic Surgeons (AAOS) and the American Orthopedic Society for Sports Medicine (AOSSM), among others, and currently serves as assistant team physician for the NFL’s San Francisco 49ers as well as head team physician for a number of Stanford University varsity athletic teams. He is actively involved in research focusing on the role of inflammatory mediators, and microRNA in particular, on cartilage and tendon damage. Dr. Abrams received his undergraduate degree from Stanford University and his doctorate of medicine from the University of California – San Diego. He completed his residency in orthopedic surgery at Stanford University and went on to receive additional training in Orthopedic Sports Medicine and Shoulder Surgery at Rush University Medical Center in Chicago, Illinois. Dr. Abrams has authored or co-authored over 60 peer-reviewed scientific articles, over 20 book chapters, has presented original research at numerous national and international scientific meetings, and serves as a reviewer for numerous sports medicine scientific journals.

Dr. William Li, Scientific Advisory Board Member
Dr. William Li is CEO and co-founder of the Angiogenesis Foundation. He trained in the lab of Dr. Judah Folkman, pioneer of the angiogenesis field, and has been actively engaged in angiogenesis research and clinical development for 30 years. Under Dr. Li’s leadership, the foundation has developed a unique social enterprise model based on value-creating collaborations with leading biopharmaceutical and medical device companies. Dr. Li is actively engaged in identifying unmet needs in the healthcare space for which clinical and cost-effective technology can offer beneficial solutions. He is a graduate of Harvard, and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as advisor and consultant to leading global public and private companies.

Mykol Larvie, Scientific Advisory Board Member
Recipient of three Harvard Medical Student Teaching awards in Principal Clinic Experience, Mykol Larvie is currently a radiologist in the Cleveland Clinic’s Divisions of Nuclear Medicine and Neuroradiology as well as the director of Functional and Molecular Neuroimaging. With a completed internship in the Department of Medicine as well residency in the Department of Radiology and fellowship in the Division of Neuroradiology at the Massachusetts General Hospital, Dr. Larvie specializes in PET examinations of the brain performed typically for the evaluation of neurodegenerative disease, seizure and tumor. He delivers didactic lectures and case conferences to residents and fellows six times per year and serves as a mentor and advisor to medical students, residents and fellows.

Nathan L. Guerette, Scientific Advisory Board Member
Nathan L. Guerette is the director and president of the Female Pelvic Medicine Institute of Virginia; an associate clinical professor in the division of Urogynecology and Pelvic Reconstructive Surgery at the Medical College of Virginia; a full clinical professor in Urogynecology and Pelvic Reconstructive Surgery at the Riverside Regional Medical Center; and the Robotic Surgery director at the Chippenham and Johnston Willis Medical Center. With a completed fellowship in urogynecology and pelvic reconstructive surgery at the Cleveland Clinic Foundation, Dr. Guerette has won seven awards in the medical and humanitarian departments. He has made nine media appearances, some of which were on PBS and NBC News. He has three board certifications and has ran a surgical mission trip to Trujillo, Peru, through Bon Secours.

Dr. Ashling O’Connor, Scientific Advisory Board Member
Currently a surgeon at the Comprehensive Breast Health Center of the Lahey Medical Center, Dr. O’Connor has won seven awards in the surgical department. She has completed a surgical internship at the Mater Misericordiae Hospital in Dublin as well as a breast surgery fellowship at the University of Massachusetts Interdisciplinary Breast Fellowship. She mentors medical students and surgical residents both in the operating room and in a clinical setting and enjoys biking and triathlons as well as trail and marathon running. She is certified in the Hidden Scar technique in breast surgery as well as in the advanced cardiac life support and is a member of the Protocol Review Committee Umass Memorial Medical Center, the New England Surgical Society and the American College of Surgeons.

Samir Awad, Scientific Advisory Board Member
Samir Awad has worked for the Department of Veterans Affairs since 2000. He has served as the operative care line associate executive, chief of general surgery, and medical director of the Surgical Intensive Care Unit at the MEDVAMC. Dr. Awad’s areas of specialty include liver, pancreas, and acute care surgery, as well as minimally invasive surgical procedures. He is a member of the Association for Academic Surgeons, the Society of University Surgeons, the American College of Surgeons, the Surgical Infection Society, and the Society for Critical Care Medicine. Dr. Awad has authored more than 100 peer-reviewed and invited publications and is the recipient of numerous awards for surgical and research achievements. Dr. Awad is certified by the American Board of Surgery and Surgical Critical Care.

Endonovo Therapeutics Inc. (ENDV), closed Thursday's trading session at $1.20, off by 7.6923%, on 101,095 volume with 113 trades. The average volume for the last 3 months is 32,703 and the stock's 52-week low/high is $0.699999988/$26.1000003.

Recent News

chart

Quest Patent Research Corp. (OTCQB: QPRC)

The QualityStocks Daily Newsletter would like to spotlight Quest Patent Research Corp. (OTCQB: QPRC).

Quest Patent Research Corp. (OTCQB: QPRC) is a New York City-based intellectual property (IP) asset management firm operating through majority-owned and controlled operating subsidiaries to deliver financial, strategic and legal resources for IP monetization. Quest currently owns, controls or manages over 115 patents across 11 intellectual property portfolios (https://www.qprc.com/portfolio). The company generates revenues from patent licensing fees of its IP property portfolios and from licensed packaging sales.

Quest creates shareholder value through investment and management interests in intellectual property assets, such as patents, trademarks, copyrights, novel inventions and trade secrets. Through its business, shareholders have the opportunity to participate across a broad portfolio of dynamic assets in the burgeoning intellectual property space.

Objectives

Invention, protection and commercialization of IP require a deep understanding of dynamic technologies, market fundamentals, competitive landscapes and engagement strategies. Often, IP asset owners/stakeholders lack the requisite resources, experience and/or capacity to access the latent value of their IP assets and opportunities. Quest seeks to bridge this gap, partnering with asset owners – such as inventors, businesses, corporations and law firms – to help them fully realize the value of IP assets through:

  • IP Valuation
  • Structured Licensing Programs
  • Patent Prosecution
  • Partial or Full Liquidity
  • Portfolio Evaluation
  • Portfolio Maintenance
  • Legal Advisory
  • Attorney/Investor Referral
  • Patent Acquisition/Liquidation

At Quest, each partnership is treated as its own entity, with its own focused management comprised of Quest employees and seasoned industry associates. Many of technologies are placed in a wholly owned subsidiary of Quest, benefitting from the broader expertise of the company’s leadership.

Management

Quest’s management team delivers a wealth of experience in strategic business management, intellectual property, finance and marketing. The company’s internal resources, in tandem with its external network of financial, legal and managerial professionals, can develop creative solutions to the myriad of challenges involved in monetizing IP. Quest’s structured diligence and deployment procedures mitigate risks, maximize returns and deliver value to IP owners and shareholders alike.

Quest CEO and President Jon Scahill was the founder and managing director of the Urban-Rigney Group, LLC, a private consultancy specializing in new business/new venture development, operations optimization, and strategic analysis. Prior to launching his consultancy business, Mr. Scahill held numerous positions in sales and marketing, technical management, and product development in the consumer products/flexible packaging arena. Mr. Scahill holds a B.S. in chemical engineering from the University of Rochester, an MBA from Rochester’s Simon Graduate School of Business, and a JD from Pace University Law School. He is a registered patent attorney admitted to practice in New York, Florida, the District of Columbia and before the United States Patent and Trademark Office.

Quest Chief Technology Officer Timothy Scahill recently completed a merger and buyout of Managed Services Team LLC, an IT Managed Services provider. Prior to Managed Services Team, he was president of Layer 8 Group Inc., which merged with Structured Technologies Inc. to form Managed Services Team LLC. In his roles he was responsible for business strategy, acquisition, execution, as well as financial management. Mr. Scahill’s entrepreneurial acumen and proven record of successful management with sole discretionary responsibility, demonstrate the scope of his capability and his value to delivering results. He successfully completed his term on the boards of the Upstate New York Technology Council and Pariemus Rochester. Mr. Scahill completed a six-year term as secretary, executive council and a seat on the board of directors for Habitat for Humanity. He has served as president of the Western New York chapter of The Entrepreneurs Organization and continues to serve on the board as accelerator chair. Mr. Scahill is currently performing Cyber Intelligence, Security and Information Assurance work for an undisclosed organization.

Peter LaFauci is president of CFO Solutions, a Rochester, NY-based consulting firm offering knowledge-based financial and accounting solutions for emerging to medium-size companies. Mr. LaFauci is a seasoned executive with over 25 years of proven success in developing, leading and executing strategy in both publicly and privately held companies within the advertising, software development, internet, manufacturing and emerging technologies sectors. Peter possesses strong research and analytical skills as well as interpreting, summarizing and communicating financial and business information to others. Mr. LaFauci is a graduate of Saint Bonaventure University.

Quest Patent Research Corp. (OTCQB: QPRC), closed Thursday's trading session at $0.008, up 6.6667%, on 87,435 volume with 8 trades. The average volume for the last 3 months is 162,525 and the stock's 52-week low/high is $0.0051/$0.039999999.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.